Literature DB >> 2702590

Patterns of occult bleeding in asymptomatic colorectal cancer.

D A Ahlquist1, D B McGill, J L Fleming, S Schwartz, H S Wieand, J Rubin, C G Moertel.   

Abstract

The assumption that asymptomatic colorectal cancers bleed provides the rationale for widespread stool screening. The authors studied 12 patients with unoperated colorectal cancer but without colorectal symptoms and six healthy volunteers as laboratory controls. All stools were collected for 2 weeks and analyzed by the HemoQuant and Hemoccult tests. In controls, the mean HemoQuant value was 0.7 mg hemoglobin (Hb)/g stool (range, 0.1-1.8) and all stools were Hemoccult-negative. In cancer patients, the mean HemoQuant was 3.3 mg Hb/g (range, 0.3-13.2); stools were within the normal HemoQuant range (less than 2 mg Hb/g) in 38% and negative by Hemoccult in 70%. The mean cancer detection rate testing a single stool per patient was 57% for HemoQuant and 25% for Hemoccult (P less than 0.001). The detection rate rose testing multiple stools and was maximal with five stools at 83% for HemoQuant compared to 31% for Hemoccult (P less than 0.001). The authors conclude that fecal blood levels are commonly normal with asymptomatic colorectal cancer. Although higher with HemoQuant than Hemoccult, cancer detection rates by fecal blood testing appear to be lower than previously reported.

Entities:  

Mesh:

Year:  1989        PMID: 2702590     DOI: 10.1002/1097-0142(19900501)63:9<1826::aid-cncr2820630928>3.0.co;2-p

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  18 in total

1.  [Conventional and molecular screening (fecal tests)].

Authors:  C Pox; K Schulmann; W Schmiegel
Journal:  Internist (Berl)       Date:  2003-03       Impact factor: 0.743

2.  Effects of high-fiber diet on fecal blood content (HemoQuant assay) in healthy subjects.

Authors:  J L Slavin; E A Melcher; M Sundeen; S Schwartz
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

3.  A simplified, non-invasive fecal-based DNA integrity assay and iFOBT for colorectal cancer detection.

Authors:  Murugan Kalimutho; Giovanna Del Vecchio Blanco; Micaela Cretella; Elena Mannisi; Pierpaolo Sileri; Amanda Formosa; Francesco Pallone; Giorgio Federici; Sergio Bernardini
Journal:  Int J Colorectal Dis       Date:  2011-01-12       Impact factor: 2.571

Review 4.  Molecular markers for colorectal cancer screening.

Authors:  Brandon T Dickinson; John Kisiel; David A Ahlquist; William M Grady
Journal:  Gut       Date:  2015-05-20       Impact factor: 23.059

5.  Novel Approach to Fecal Occult Blood Testing by Assay of Erythrocyte-Specific microRNA Markers.

Authors:  Chung Wah Wu; Xiaoming Cao; Calise K Berger; Patrick H Foote; Douglas W Mahoney; Julie A Simonson; Bradley W Anderson; Tracy C Yab; William R Taylor; Lisa A Boardman; John B Kisiel; David A Ahlquist
Journal:  Dig Dis Sci       Date:  2017-06-28       Impact factor: 3.199

Review 6.  Multi-Target Stool DNA Test: Is the Future Here?

Authors:  Seth Sweetser; David A Ahlquist
Journal:  Curr Gastroenterol Rep       Date:  2016-06

Review 7.  Occult and obscure gastrointestinal bleeding: causes and clinical management.

Authors:  Don C Rockey
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-03-30       Impact factor: 46.802

8.  Molecular biology. Setting the stage in colorectal cancer?

Authors:  H E Mulcahy; D P O'Donoghue
Journal:  Gut       Date:  1993-11       Impact factor: 23.059

9.  Patient perceptions of stool DNA testing for pan-digestive cancer screening: a survey questionnaire.

Authors:  Dennis Yang; Shauna L Hillman; Ann M Harris; Pamela S Sinicrope; Mary E Devens; David A Ahlquist
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

10.  Evaluation of specific fecal protein biochips for the diagnosis of colorectal cancer.

Authors:  Hui-Peng Wang; Yang-Yun Wang; Jie Pan; Rong Cen; Yuan-Kun Cai
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.